Novartis Ag (NVS) 82.21 $NVS
Global Chronic Obstructive Pulmonary Disease Drugs Market Growth of 4.85% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Merck, Almirall, Novartis - Research and Markets
BusinessWire - Wed Aug 03, 12:23PM CDT
Research and Markets has announced the addition of the "Global Chronic Obstructive Pulmonary Disease Drugs Market 2016-2020" report to their offering.
MRK: 57.66 (+0.01), NVS: 82.21 (-0.19)
Global Pharmaceuticals Market Analytics Report 2016 Featuring Pfizer, Roche, Merk & Co., Sanofi, Gilead Sciences, Johnson & Johnson, Novartis, Abbvie, Amgen, GSK - Research and Markets
BusinessWire - Wed Aug 03, 8:13AM CDT
Research and Markets has announced the addition of the "Pharmaceuticals Global Market Analytics Report 2016" report to their offering.
JNJ: 124.45 (+0.55), GILD: 80.37 (+0.28), NVS: 82.21 (-0.19)
Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
PR Newswire - Wed Aug 03, 6:00AM CDT
Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LEE011 (ribociclib), in combination with letrozole, for the treatment of hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. LEE011 is a selective cyclin dependent kinase (CDK4/6) inhibitor.
NVS: 82.21 (-0.19)
Xencor Reports Second Quarter 2016 Financial Results
PR Newswire - Tue Aug 02, 3:01PM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported financial results for the second quarter ended June 30, 2016 and provided a review of pipeline and corporate highlights.
XNCR: 21.16 (+1.88), NVS: 82.21 (-0.19)
What Awaits Radius Health (RDUS) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:02AM CDT
Radius Health (RDUS) is scheduled to report second-quarter 2016 results on Aug 4.
IPXL: 31.62 (+0.65), RDUS: 53.00 (+4.02), IRWD: 14.24 (+0.41), NVS: 82.21 (-0.19)
Alcon achieves US approval for CyPass(R) Micro-Stent, a micro invasive surgical device to treat glaucoma
Globe Newswire - Tue Aug 02, 12:15AM CDT
Novartis International AG / Alcon achieves US approval for CyPass(R) Micro-Stent, a micro invasive surgical device to treat glaucoma . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 82.21 (-0.19)
Neurologists Report Increasing Payer Pressure For Disease-Modifying Therapies, Resulting In Suboptimal Treatment For Some Patients With Multiple Sclerosis
PR Newswire - Mon Aug 01, 10:40AM CDT
In the Q2 update of RealTime Dynamix(TM): Multiple Sclerosis, roughly one-quarter of the respondents reported increased payer restrictions for Teva's Copaxone while restrictions have eased somewhat for Sandoz's Glatopa, Novartis' Extavia and Biogen's Tecfidera. While half of the neurologists agreed that payers are becoming more aggressive with MS patient management, only one-quarter stated that payer policies are strongly influencing their use of specific DMT brands.
NVS: 82.21 (-0.19)
What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 79.66 (+2.75), BIIB: 321.00 (-0.34), ABT: 44.95 (-0.12), JNJ: 124.45 (+0.55), GILD: 80.37 (+0.28), MRK: 57.66 (+0.01), PFE: 35.49 (+0.20), SGNT: 21.71 (-0.03), ABBV: 66.57 (-0.21), PRTA: 58.27 (+2.66), NVS: 82.21 (-0.19)
CutisPharma Appoints Steven Dinh As Chief Scientific Officer
PR Newswire - Mon Aug 01, 5:00AM CDT
CutisPharma today announced the appointment of Steven Dinh, Sc.D., as Executive Vice President and Chief Scientific Officer. In this key role, Dinh will oversee the Company's efforts to develop its pipeline of drugs for New Drug Application (NDA) submission to the U.S. Food and Drug Administration.
NVS: 82.21 (-0.19)
What Awaits ACUR & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:43AM CDT
Medical is one of the six sectors that are projected to record positive earnings growth this quarter.
ABT: 44.95 (-0.12), JNJ: 124.45 (+0.55), GILD: 80.37 (+0.28), NVLS: 4.83 (+0.02), CYTR: 0.62 (unch), CEMP: 22.41 (+0.21), ACUR: 1.88 (+0.04), NVS: 82.21 (-0.19)
After Yesterday's Decline of 1.24%, Novartis Offers Investors Better Value
Comtex SmarTrend(R) - Thu Jul 28, 1:21PM CDT
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $81.57 to a high of $82.58. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $82.27 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVS: 82.21 (-0.19)
Look for Shares of Novartis to Potentially Rebound after Yesterday's 1.24% Sell Off
Comtex SmarTrend(R) - Thu Jul 28, 1:19PM CDT
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $81.57 to a high of $82.58. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $82.27 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVS: 82.21 (-0.19)
Glaxo (GSK) Beats Q2 Earnings Estimates, Revenues Up Y/Y
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:59AM CDT
Glaxo (GSK) reported second-quarter 2016 core earnings of 70 cents per American depositary share, beating the Zacks Consensus Estimate of 55 cents.
INVA: 13.01 (+0.17), ANIP: 65.00 (+2.90), GSK: 44.82 (-0.21), NVS: 82.21 (-0.19)
Novartis (NVS) Beats Earnings & Sales in Q2
Ekta Bagri - Zacks Investment Research - Tue Jul 19, 1:07AM CDT
Novartis beat on earnings in the second quarter of 2016.
NVS: 82.21 (-0.19)
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
Globe Newswire - Tue Jul 19, 12:01AM CDT
Novartis International AG / Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 82.21 (-0.19)
Why Earnings Season Could Be Great for Novartis AG (NVS)
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 9:12AM CDT
Novartis AG (NVS) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Rank perspective.
NVS: 82.21 (-0.19)
Abbott Labs (ABT) Q2 Earnings: Will the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 8:37AM CDT
Abbott Laboratories (ABT) is scheduled to report second-quarter 2016 results before the opening bell on Jul 20.
ABT: 44.95 (-0.12), JNJ: 124.45 (+0.55), GILD: 80.37 (+0.28), NVS: 82.21 (-0.19)
3 Drug Stocks to Report Earnings on Jul 19: JNJ, NVS, NEOG
Arpita Dutt - Zacks Investment Research - Mon Jul 18, 7:02AM CDT
Three drug stocks including industry bellwether Johnson & Johnson (JNJ) will report results on Jul 19.
JNJ: 124.45 (+0.55), AMGN: 173.43 (-0.72), NEOG: 55.27 (-0.14), NVS: 82.21 (-0.19)
Global Psoriasis Market Outlook to 2020 - Key Players are Johnson and Johnson, Abbvie, Amgen & Novartis - Research and Markets
BusinessWire - Mon Jul 18, 6:18AM CDT
Research and Markets has announced the addition of the "Global Psoriasis Market with Focus on Plaque Psoriasis: Outlook to 2020" report to their offering.
NVS: 82.21 (-0.19)
Global Chronic Obstructive Pulmonary Disease Drugs Market Growth of 4.85% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Merck, Almirall, Novartis - Research and Markets
BusinessWire - Wed Aug 03, 12:23PM CDT
Research and Markets has announced the addition of the "Global Chronic Obstructive Pulmonary Disease Drugs Market 2016-2020" report to their offering.
MRK: 57.66 (+0.01), NVS: 82.21 (-0.19)
Global Pharmaceuticals Market Analytics Report 2016 Featuring Pfizer, Roche, Merk & Co., Sanofi, Gilead Sciences, Johnson & Johnson, Novartis, Abbvie, Amgen, GSK - Research and Markets
BusinessWire - Wed Aug 03, 8:13AM CDT
Research and Markets has announced the addition of the "Pharmaceuticals Global Market Analytics Report 2016" report to their offering.
JNJ: 124.45 (+0.55), GILD: 80.37 (+0.28), NVS: 82.21 (-0.19)
Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
PR Newswire - Wed Aug 03, 6:00AM CDT
Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LEE011 (ribociclib), in combination with letrozole, for the treatment of hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. LEE011 is a selective cyclin dependent kinase (CDK4/6) inhibitor.
NVS: 82.21 (-0.19)
Xencor Reports Second Quarter 2016 Financial Results
PR Newswire - Tue Aug 02, 3:01PM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported financial results for the second quarter ended June 30, 2016 and provided a review of pipeline and corporate highlights.
XNCR: 21.16 (+1.88), NVS: 82.21 (-0.19)
What Awaits Radius Health (RDUS) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:02AM CDT
Radius Health (RDUS) is scheduled to report second-quarter 2016 results on Aug 4.
IPXL: 31.62 (+0.65), RDUS: 53.00 (+4.02), IRWD: 14.24 (+0.41), NVS: 82.21 (-0.19)
Alcon achieves US approval for CyPass(R) Micro-Stent, a micro invasive surgical device to treat glaucoma
Globe Newswire - Tue Aug 02, 12:15AM CDT
Novartis International AG / Alcon achieves US approval for CyPass(R) Micro-Stent, a micro invasive surgical device to treat glaucoma . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 82.21 (-0.19)
Neurologists Report Increasing Payer Pressure For Disease-Modifying Therapies, Resulting In Suboptimal Treatment For Some Patients With Multiple Sclerosis
PR Newswire - Mon Aug 01, 10:40AM CDT
In the Q2 update of RealTime Dynamix(TM): Multiple Sclerosis, roughly one-quarter of the respondents reported increased payer restrictions for Teva's Copaxone while restrictions have eased somewhat for Sandoz's Glatopa, Novartis' Extavia and Biogen's Tecfidera. While half of the neurologists agreed that payers are becoming more aggressive with MS patient management, only one-quarter stated that payer policies are strongly influencing their use of specific DMT brands.
NVS: 82.21 (-0.19)
What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 79.66 (+2.75), BIIB: 321.00 (-0.34), ABT: 44.95 (-0.12), JNJ: 124.45 (+0.55), GILD: 80.37 (+0.28), MRK: 57.66 (+0.01), PFE: 35.49 (+0.20), SGNT: 21.71 (-0.03), ABBV: 66.57 (-0.21), PRTA: 58.27 (+2.66), NVS: 82.21 (-0.19)
CutisPharma Appoints Steven Dinh As Chief Scientific Officer
PR Newswire - Mon Aug 01, 5:00AM CDT
CutisPharma today announced the appointment of Steven Dinh, Sc.D., as Executive Vice President and Chief Scientific Officer. In this key role, Dinh will oversee the Company's efforts to develop its pipeline of drugs for New Drug Application (NDA) submission to the U.S. Food and Drug Administration.
NVS: 82.21 (-0.19)
What Awaits ACUR & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:43AM CDT
Medical is one of the six sectors that are projected to record positive earnings growth this quarter.
ABT: 44.95 (-0.12), JNJ: 124.45 (+0.55), GILD: 80.37 (+0.28), NVLS: 4.83 (+0.02), CYTR: 0.62 (unch), CEMP: 22.41 (+0.21), ACUR: 1.88 (+0.04), NVS: 82.21 (-0.19)
After Yesterday's Decline of 1.24%, Novartis Offers Investors Better Value
Comtex SmarTrend(R) - Thu Jul 28, 1:21PM CDT
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $81.57 to a high of $82.58. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $82.27 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVS: 82.21 (-0.19)
Look for Shares of Novartis to Potentially Rebound after Yesterday's 1.24% Sell Off
Comtex SmarTrend(R) - Thu Jul 28, 1:19PM CDT
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $81.57 to a high of $82.58. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $82.27 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVS: 82.21 (-0.19)
Glaxo (GSK) Beats Q2 Earnings Estimates, Revenues Up Y/Y
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:59AM CDT
Glaxo (GSK) reported second-quarter 2016 core earnings of 70 cents per American depositary share, beating the Zacks Consensus Estimate of 55 cents.
INVA: 13.01 (+0.17), ANIP: 65.00 (+2.90), GSK: 44.82 (-0.21), NVS: 82.21 (-0.19)
Novartis (NVS) Beats Earnings & Sales in Q2
Ekta Bagri - Zacks Investment Research - Tue Jul 19, 1:07AM CDT
Novartis beat on earnings in the second quarter of 2016.
NVS: 82.21 (-0.19)
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
Globe Newswire - Tue Jul 19, 12:01AM CDT
Novartis International AG / Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 82.21 (-0.19)
Why Earnings Season Could Be Great for Novartis AG (NVS)
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 9:12AM CDT
Novartis AG (NVS) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Rank perspective.
NVS: 82.21 (-0.19)
Abbott Labs (ABT) Q2 Earnings: Will the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 8:37AM CDT
Abbott Laboratories (ABT) is scheduled to report second-quarter 2016 results before the opening bell on Jul 20.
ABT: 44.95 (-0.12), JNJ: 124.45 (+0.55), GILD: 80.37 (+0.28), NVS: 82.21 (-0.19)
3 Drug Stocks to Report Earnings on Jul 19: JNJ, NVS, NEOG
Arpita Dutt - Zacks Investment Research - Mon Jul 18, 7:02AM CDT
Three drug stocks including industry bellwether Johnson & Johnson (JNJ) will report results on Jul 19.
JNJ: 124.45 (+0.55), AMGN: 173.43 (-0.72), NEOG: 55.27 (-0.14), NVS: 82.21 (-0.19)
Global Psoriasis Market Outlook to 2020 - Key Players are Johnson and Johnson, Abbvie, Amgen & Novartis - Research and Markets
BusinessWire - Mon Jul 18, 6:18AM CDT
Research and Markets has announced the addition of the "Global Psoriasis Market with Focus on Plaque Psoriasis: Outlook to 2020" report to their offering.
NVS: 82.21 (-0.19)
